Infection
In the first 100 days post-transplant, 195 (57%) patients had at least one documented infection; 80 (23.3%) had a SBI, 153 (44%) had viremia/viruria, and 14 (4%) had an invasive fungal infection. The median days to infection was 19 (IQR 10.5-32.5).
After adjusting for HSCT type, there was a 4.91 (95% CI 1.40-17.24; p=0.013) fold increased hazard of infection with every doubling of pre-HSCT glucose CV (Table 3, Figure 3). While there was no association between pre-HSCT glucose CV and odds of SBI or fungal infection in the first 100 days, among allogeneic HSCT patients, the odds of viremia was 1.77 (95% 1.23-2.56; p=0.002) fold higher with each doubling of pre-HSCT glucose CV. Because 71% of infections occurred in the first 30 days, it was not possible to evaluate for an association between day 0-30 post-HSCT glucose CV and time-to-infection due to overlapping intervals.